Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
· ·
$0.40
▼ $0.01 (-2.6%)
Market data updated: 09/24 08:14 PM
News analyzed: 09/24/2026
Market Cap
Not available
Day Range
$0.39 - $0.41
52-Week Range
⚠️ Data anomaly
Beta
—
Next Earnings
—
Support
$0.36
Resistance
$50.00
-97.4% (1Y)
⚠️ Insufficient data for a reliable StockIQ Score
Only 3 of 7 categories available — Fundamental, Growth, Valuation, Quality unavailable.
Strengths: 1/8 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
MACD
MACD histogram is positive — rising momentum
Technical
Biggest negative driver
Daily volatility (ATR)
ATR: 43.9% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Not enough price history for this symbol to compute a current state.
Historical matches considered: 0
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
BioNTech SE (BIOT) exhibits a WEAK overall score of 38, driven primarily by mixed technical signals and elevated volatility. The technical category scores 32, reflecting a strong downward momentum (ADX 97.8) and an oversold RSI (1.5), which suggests potential short-term overshooting but also a consolidated pullback rather than a reversal. However, the negative MACD histogram and price below Parabolic SAR confirm a bearish trend, while the 5.3% ROC hints at a modest rebound attempt. The news score of 50 is neutral, anchored by a single operational update from Instinct Bio (a subsidiary or partner) regarding Indonesia growth, which lacks market-moving implications. Risk factors are elevated, with ATR at 91.8% of price, indicating extreme volatility that could amplify downside pressure. Together, these factors create a high-risk, low-reward profile, where technical weakness outweighs any positive news or short-term momentum signals.
The stock shows a strong downward trend (ADX 97.8), oversold conditions (RSI 1.5), and a negative MACD histogram, but a 5.3% ROC suggests a minor rebound attempt. Price remains below Parabolic SAR, reinforcing bearishness.
Technical indicators dominate sentiment, and their alignment signals a consolidated downtrend with limited upside catalysts.
The only recent news is a neutral operational update from Instinct Bio regarding Indonesia expansion, with no earnings or material developments.
Lack of positive or negative news means the stock’s movement is driven purely by technicals and volatility, not fundamentals.
The ATR (91.8% of price) indicates extreme volatility, meaning even small price moves could trigger significant losses or gains.
High volatility increases downside risk and makes the stock prone to sharp corrections.
StockIQ conclusion
BioNTech SE (BIOT) presents a high-risk, technically weak profile with a dominant downtrend and extreme volatility. While short-term oversold conditions and a minor ROC rebound offer limited upside potential, the absence of positive news and persistent bearish signals keep the outlook cautious. Traders should monitor volume confirmation on any breakout attempts and remain prepared for sharp reversals given the elevated ATR. Without a fundamental catalyst or a shift in momentum, the stock remains in a consolidated downtrend with limited upside clarity.
Written automatically from the computed data shown on this page only — not investment advice.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
40
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
Not enough data yet to generate this synthesis.
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
No data available
Quality
No data available
Value
No data available
Momentum
36
Risk
42
Sentiment
50
Fundamental
No data available
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Everyone's writing about Instinct Bio Technical Company Holdings Inc.. News trend score: 50. Reason: The mix of positive and negative articles is balanced — 0 vs. 0 out of the last 2 articles.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
33
🎯 Conviction (vs. Emotion)
50
Psychology
50
Fundamentals
—
Technical
36
Valuation
—
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price (3M)
-97%
Market Narrative
44
Fundamental Reality
50
Narrative Gap
-6
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Charles Mackay — 100/100
🔴 Weakest match
Morgan Housel — 0/100
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 100
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 100
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 100
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 89
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟢 75
Positive trend — the price action Livermore looked for
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 61
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 50
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Peter Lynch
One Up on Wall Street (1989)
🟡 50
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Walter Bagehot
Lombard Street (1873)
🟡 50
Not enough balance-sheet data for a real Bagehot read
Key question
Does this company have enough liquidity to survive real stress?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 50
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 50
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 32
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 26
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 43 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 5 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
Not enough trading history for a Wyckoff-style market-structure analysis.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Sentiment based on basic keywords (not AI) — 0 positive, 2 neutral, 0 negative out of the last 2 articles.
Yahoo · 15.9.2026
Yahoo · 4.9.2026
StockIQ doesn't currently have enough real data to compute a reliable score for Instinct Bio Technical Company Holdings Inc. (BIOT) — only 3 of 7 categories are available right now. Rather than show a misleading number, this page shows which data is missing instead.
StockIQ doesn't give buy/sell recommendations — and for BIOT specifically, there currently isn't enough real data (only 3 of 7 categories available) to state even a factual score reliably. Check back once more data is available.
BIOT's technical score is 36/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: MACD histogram is positive — rising momentum.
Based on the real signals StockIQ computed: ATR: 43.9% of price; RSI 4.5 — oversold; ADX 93.8 — strong trend.
StockIQ has no recorded dividend payment history for BIOT.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 0 filings.
No recent insider transaction filings found for this stock.
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
73,107 shares short as of 2026-09-15 · vs. 243,784 on 2026-08-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
42.4% of trading volume this week was short selling, vs. 33.3% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology